

Programme 30 March 2006

- 9.00am Registration and Coffee
- 10.00am New Insights on Pulmonary Vascular Disease
Royal Society, 6–9 Carlton House Terrace, London SW1Y 5AG
Welcome: Professor Sir Magdi Yacoub/Overview: Professor Al Fishman
- 10.15am Insights into Pulmonary Vascular Disease from Vascular Biology and Vascular Medicine
John Cooke, Stanford University Medical Center
- 10.45am Paediatric Manifestations of Pulmonary Vascular Disease and Early Intervention Strategies
Robyn Barst, Columbia University College of Physicians and Surgeons
- 11.15am Paediatric Roundtable Discussion
Chair: Sheila G Haworth, University of London
- 11.30am Gene Therapy Strategies for ILD & IPH
Duncan Stewart, University of Toronto
- 12.00pm Lunch at Royal Society
- 1.30pm Role of BMPs in Pulmonary Hypertension
Adrian Chester, Imperial College, London
- 2.00pm Role of Erythrocytes in the Pathophysiology and Treatment of PPT
Randy Sprague, St Louis University School of Medicine
- 2.30pm Similarities and Differences in Neurohormonal Factors Impacting upon Different Types of Pulmonary Vascular Disease
Robert Naeije, Erasme University Hospital
- 3.00pm Roundtable Discussion
Chair: Chris Thiemermann, William Harvey Research Institute, London
- 3.15pm Coffee Break
- 3.45pm Deficiency of the VIP Gene as a Potential Cause of Primary Pulmonary Hypertension
Sami Said, SUNY Health Sciences Center, Stony Brook
- 4.15pm Implantable Gas Exchange Module as a Bridge to Lung Transplantation
Iker Mallabiabarrena, Geneva
- 4.45pm Adjournment

Programme 31 March 2006

- 9.00am Coffee
- 9.30am New Insights into Prostacyclin Science
Royal Society, 6–9 Carlton House Terrace, London SW1Y 5AG
Welcome: Professor Sir Magdi Yacoub/Overview: Professor Al Fishman
- 9.45am Clinical Experience in Combining Prostacyclin and Its Analogs, ERAs and PDE₅ Inhibitors
Lewis Rubin, UCSD
- 10.15am Combination Therapy Roundtable Discussion
Chair: Ghazwan Butrous, Pfizer Global R&D
- 10.30am Inhalation Therapy: Where in the Combination?
Roundtable Discussion
Chair: Robert Bourge, UAB
- 10.45am Coffee Break
- 11.15am Genetic Predispositions Related to Prostacyclin Deficiency and Possible RNA Interference Strategies
Richard Trembath, King's College London
- 11.45am Genetics/RNA Interference Roundtable Discussion
Chair: John Newman, Vanderbilt University School of Medicine
- 12.00pm Scleroderma Associated PPH
Chris Denton, Royal Free and University College Medical School
- 12.30pm Treatment with Prostacyclin for SPH/ILD/IPF Roundtable Discussion
Chair: Sanjay Mehta, London Health Sciences Centre
- 12.45pm Lunch at Royal Society
- 2.00pm Prospects of Prostacyclin or Its Analogs in Treating Sub-Types of Left Heart Failure
Vallerie McLaughlin, University of Michigan
- 2.30pm CHF Roundtable Discussion
Chairs: Vallerie McLaughlin, University of Michigan and Professor Sir Magdi Yacoub
- 2.45pm Sustained Release Formulations of Prostacyclin Analogs – Is Long-Term Zero-Order Release on the Horizon?
Roger Jeffs, United Therapeutics
- 3.15pm Beraprost Efficacy Roundtable Discussion
Chair: Tim Higenbottam, AstraZeneca
- 3.30pm Symposium Summary and Wrap Up
Co-Chairs